Constantine S. Tam

Research interests

Publications

• Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2300696

• Genomic profiling for clinical decision making in lymphoid neoplasms

  Blood · 2022 · https://doi.org/10.1182/blood.2022015854

• Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2211582

• Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00293-5

• Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00224-5

• Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00375-2

• A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

  Blood · 2020 · https://doi.org/10.1182/blood.2020006844

• COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

  Leukemia · 2020 · https://doi.org/10.1038/s41375-020-0959-x

• Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

  Blood · 2019 · https://doi.org/10.1182/blood.2019001160

• Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

  American Journal of Hematology · 2019 · https://doi.org/10.1002/ajh.25638

• Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1802917

• Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1804980

• Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

  Cancer Discovery · 2018 · https://doi.org/10.1158/2159-8290.cd-18-1119

• Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1715519

• The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

  Blood · 2018 · https://doi.org/10.1182/blood-2018-05-850461

• Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30618-1

• Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30012-8

• The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

  Blood · 2016 · https://doi.org/10.1182/blood-2016-01-688796

• Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30632-5

• Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30212-1

• Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

  Blood · 2016 · https://doi.org/10.1182/blood-2016-01-689422

• Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1509388

• Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

  Blood · 2015 · https://doi.org/10.1182/blood-2015-09-667675

• Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling

  Blood · 2014 · https://doi.org/10.1182/blood-2014-10-604272

• Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1400376

• Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

  Blood · 2008 · https://doi.org/10.1182/blood-2008-02-140582

Current projects

No projects listed.